Sanjivani Parenteral Limited has launched a postal ballot process to seek shareholder approval for the appointment of Mr. Basant Shrivastava as a Non-Executive Independent Director. This move comes as part of the company's efforts to strengthen its board with experienced professionals.

Key Details of the Postal Ballot

About Mr. Basant Shrivastava

Mr. Shrivastava, aged 69, brings over four decades of pharmaceutical industry experience to Sanjivani Parenteral Limited. His expertise lies primarily in sales and marketing, with a career that includes:

• Starting at Johnson & Johnson
• Founding Vita Pharma Agencies
• Current role as Joint Director at Joint Force Pharma Ltd

Additionally, Mr. Shrivastava holds directorships in Panchsheel Organics Limited, where he chairs the Audit Committee and is a member of the Nomination and Remuneration Committee and Stakeholders Relationship Committee.

Voting Process

The company has engaged MUFG Intime India Private Limited (formerly Link Intime India Private Limited) to facilitate the e-voting process. Shareholders whose names appear in the Register of Members or Register of Beneficial Owners as of October 31, 2025 (the cut-off date) are eligible to participate in the e-voting.

Board's Recommendation

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has proposed this appointment. They have recommended shareholders to approve the resolution for Mr. Shrivastava's appointment as an Ordinary Resolution.

Sanjivani Parenteral Limited's move to appoint Mr. Basant Shrivastava reflects the company's commitment to enhancing its board with experienced professionals from the pharmaceutical industry. Shareholders now have the opportunity to voice their decision through the e-voting process, with the results set to shape the company's leadership structure for the coming years.

Sanjivani Paranteral Limited , a prominent player in the pharmaceutical industry, has announced a significant addition to its leadership team. The company's Board of Directors has appointed Mr. Basant Shrivastava as an Additional Director under the Independent Category, effective September 11, 2025. This appointment, subject to shareholder approval at the upcoming Annual General Meeting, marks a strategic move to enhance the company's governance and industry expertise.

Appointment Details

Mr. Shrivastava, holding the Director Identification Number (DIN) 02645245, has been appointed for a five-year term as a Non-Executive Independent Director. The decision comes on the recommendation of the Nomination and Remuneration Committee, underlining the company's commitment to strengthening its board with experienced professionals.

Professional Background

Basant Shrivastava brings an impressive four decades of pharmaceutical industry experience to Sanjivani Paranteral. His educational background includes:

• M.Sc. in Chemistry
• MBA from the Jamnalal Bajaj Institute of Management Studies

Throughout his career, Shrivastava has held several leadership positions that showcase his expertise in the pharmaceutical sector:

Expertise and Achievements

Mr. Shrivastava is renowned for his sales and marketing acumen in the pharmaceutical industry. His career highlights include:

• Driving growth and launching new ventures
• Leading high-performing teams
• Spearheading operations in contrast media products
• Successfully transitioning businesses to adapt to evolving market dynamics
• Achieving numerous sales awards and consistently ranking among top performers

Board Meeting Outcome

The appointment was approved during a board meeting held on September 11, 2025. The meeting, which commenced at 06:30 P.M. and concluded at 07:00 P.M., also addressed other company matters.

Corporate Governance

It's worth noting that Mr. Shrivastava is not related to any existing directors of Sanjivani Paranteral Limited, ensuring independence in his role. This appointment aligns with the company's commitment to maintaining strong corporate governance practices.

The addition of Basant Shrivastava to Sanjivani Paranteral's board is expected to bring valuable insights and strategic direction, leveraging his extensive experience in the pharmaceutical industry. Shareholders will have the opportunity to ratify this appointment at the forthcoming Annual General Meeting, as the company continues to strengthen its leadership for future growth and success.